Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

th year running and the awards ceremony will take place on November 18, 2009 in London.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to have been shortlisted for both the Biotech Company of the Year and Licensing Deal of the Year awards at this prestigious awards event. The nominations are a testament to the significant achievements and progress ThromboGenics has made over the last year. The Company is now in the best position to achieve its aim of becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines. We are very proud to be nominated amongst some of the most successful companies in the industry, and look forward to the results in November."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About Scrip World Pharmaceutical
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... In late 2012, Dr. Sarah Hart, of Palm Clinic ... about Appearance Medicine . Although Dr. Hart regularly teaches ... to lecture in China, and quite a different experience it ... 12 and 7 million people respectively. Interest in cosmetic facial ... in time. As Dr. Hart passed through the Fuzhou airport ...
(Date:5/16/2013)... Cambridge Healthtech Institute will host its ... at the Renaissance Waterfront Hotel in Boston, MA. ... look at the current strategies and innovations for optimizing ... Leaders in the field will reveal how their work ... greater specificity and efficiency. , “In this age of ...
(Date:5/16/2013)...  HealthSparq, a trusted provider of healthcare transparency ... health plans, will debut a new benchmark study ... 2013 conference on June 13.  The presentation will ... insurance companies across the country are thinking about ... for increased healthcare transparency. This ...
(Date:5/16/2013)... 2013 Scientists at the Center for Learning ... and the California -based biopharmaceutical company ... therapy for reversing memory decline in mice with Alzheimer,s ... cognitive improvement in advanced stage AD mice. The study ... cognitive decline for advanced stage AD mice, and is ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3
... Genome Research Institute (NHGRI) of the National Institutes of ... to date to chart the genetic changes involved in ... The findings should help pave the way for more ... cause of cancer deaths. , In a paper published ...
... team of scientists has performed the ultimate miniaturisation of ... atom. This breakthrough is a key step in bringing ... on the fundamental theory of quantum mechanics which could ... quantum world, objects such as atoms are allowed to ...
... PALO ALTO, Calif., Oct. 22 Telik, Inc.,(Nasdaq: ... call and,webcast will be held on Wednesday, November 5, ... following the release earlier that day of the,company,s financial ... The conference call will be accessible via Telik,s ...
Cached Biology Technology:Large-scale genetic study sheds new light on lung cancer 2Large-scale genetic study sheds new light on lung cancer 3Large-scale genetic study sheds new light on lung cancer 4Large-scale genetic study sheds new light on lung cancer 5Memoirs of a qubit: Hybrid memory solves key problem for quantum computing 2
(Date:5/17/2013)... international team of scientists using a new X-ray method ... living frog embryo in greater detail than ever before., ... research and the search for new treatments for genetic ... fr Technologie in Germany, in collaboration with the Advanced ... National Laboratory, released the most precise depiction ever of ...
(Date:5/16/2013)... MARC (Maximizing Access to Research Careers) Program has ... Society (ENDO) 95th Annual Meeting in San Francisco, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
(Date:5/16/2013)... adults living closer to a fast food restaurant had ... lived further away from fast food, according to researchers ... and this association was particularly strong among those with ... online in the American Journal of Public Health ... a fast food restaurant, and among lower-income African-Americans, the ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3
... that enables malaria parasites to invade red blood cells, ... design and vaccine development. The findings are reported in ... Malaria causes approximately 400 million clinical cases and 2 ... occurring among children. The disease is caused by mosquito-borne ...
... Technology have created the first nanodevices capable of ... to new forms of molecular identification that are ... as revolutionary new instruments for proteomics. , According ... and bioengineering at Caltech and the founding director ...
... that makes it possible to zoom in on smaller ... Dana-Farber Cancer Institute have identified nearly 100 chromosome regions ... cell lung cancer. The findings provide new clues about ... common type of lung cancer –?and one of the ...
Cached Biology News:Malaria mechanism revealed 2Team Invents Device For Weighing Individual Molecules 2Team Invents Device For Weighing Individual Molecules 3High-powered gene profiles provide clues to genes involved in common form of lung cancer 2High-powered gene profiles provide clues to genes involved in common form of lung cancer 3
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
6-keto Prostaglandin F1α EIA Antiserum 6-keto-PGF1alpha EIAs prostaglandins antisera enzyme immunoassays reagents 6-keto-PGF1.alpha....
...
Ephrin A4...
Biology Products: